Clinical ResearchInterventional CardiologyShort-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years: Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial
Interventional Cardiology
Under an Elsevier user license
open archive
Key Words
graft occlusion
mortality
stent thrombosis
SYNTAX
Abbreviations and Acronyms
ARC
Academic Research Consortium
CABG
coronary artery bypass graft
CEC
clinical events committee
GO
graft occlusion
KM
Kaplan-Meier
LAD
left anterior descending artery
LIMA
left internal mammary artery
MI
myocardial infarction
PCI
percutaneous coronary intervention
RIMA
right internal mammary artery
ST
stent thrombosis
ULMCA
unprotected left main coronary artery
Cited by (0)
The SYNTAX trial was funded by Boston Scientific. Dr. Mack has served on the Speakers’ Bureau of Boston Scientific, Cordis, and Medtronic. Dr. Feldman has served on the Speakers’ Bureau of Boston Scientific; received grant support from Abbott Laboratories, Atritech, Boston Scientific, Edwards, and Evalve; and served as a consultant for Abbott Laboratories, Boston Scientific, Coherex, Edwards, InterValve, Square One, and W. L. Gore and Associates. Dr. Morice’s institution has received a research grant from Boston Scientific. Dr. Dawkins is a full-time employee and stockholder of Boston Scientific. All other authors have reported that they have no relationships relevant to the content of this paper to disclose.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.